Burning Rock Biotech (NASDAQ:BNR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Burning Rock Biotech (NASDAQ:BNR) from a hold rating to a buy rating in a report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Burning Rock Biotech Price Performance

BNR opened at $32.01 on Friday. The firm has a market capitalization of $344.43 million, a PE ratio of -19.28 and a beta of 1.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91. The business’s 50-day moving average is $20.04 and its two-hundred day moving average is $12.41. Burning Rock Biotech has a 1 year low of $2.18 and a 1 year high of $34.79.

Hedge Funds Weigh In On Burning Rock Biotech

A number of institutional investors have recently bought and sold shares of the business. Prospera Financial Services Inc acquired a new stake in shares of Burning Rock Biotech in the third quarter worth $214,000. China Universal Asset Management Co. Ltd. acquired a new stake in Burning Rock Biotech during the 3rd quarter worth about $26,000. Finally, Crcm LP raised its stake in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after buying an additional 26,809 shares during the last quarter. 30.03% of the stock is owned by hedge funds and other institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.